Bronstein, Gewirtz & Grossman, LLC Investigates Potential Securities Fraud Claims Against Sage Therapeutics, Inc.
NEW YORK, NY – In a recent press release on March 9, 2025, Bronstein, Gewirtz & Grossman, LLC, a prominent securities fraud class action law firm, announced that it is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. (Sage or the Company) (NASDAQ: SAGE). The investigation pertains to allegations of securities fraud against the biopharmaceutical company.
Background on Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines to transform the lives of patients with debilitating central nervous system (CNS) disorders. The company’s primary focus is on developing and commercializing therapeutics for depression, neuropsychiatric rare disorders, and neurodegenerative diseases. Sage’s most well-known product is Zulresso (brexanolone), the first and only FDA-approved treatment for postpartum depression.
Investigation Details
Bronstein, Gewirtz & Grossman, LLC is encouraging investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, to obtain additional information and assist the investigation. The investigation focuses on whether Sage Therapeutics and certain of its executives and directors violated the federal securities laws by making false and/or misleading statements and/or failed to disclose material adverse information to investors.
Impact on Individual Investors
If you are an affected investor, you may have legal options. The potential harm to individual investors includes significant financial losses and potential damage to their portfolios. The investigation seeks to recover damages on behalf of injured parties. If you wish to learn more about the investigation, please visit bgandg.com/SAGE, or contact the firm directly.
Global Implications
The potential securities fraud investigation against Sage Therapeutics could have far-reaching implications for the biopharmaceutical industry as a whole. Investors may become increasingly cautious when investing in companies in the sector, leading to a decrease in market confidence and potential volatility. Additionally, regulatory bodies may take a closer look at the industry, potentially leading to increased scrutiny and potential regulatory changes.
Conclusion
Bronstein, Gewirtz & Grossman, LLC’s investigation into potential securities fraud claims against Sage Therapeutics, Inc. is an important development for investors and the biopharmaceutical industry. The investigation has the potential to impact individual investors who purchased Sage securities prior to April 12, 2021, and may also have broader implications for the industry as a whole. As the investigation progresses, it is essential for investors to stay informed and seek professional guidance if necessary.
- Bronstein, Gewirtz & Grossman, LLC is investigating potential securities fraud claims against Sage Therapeutics, Inc.
- The investigation pertains to allegations of securities fraud against the biopharmaceutical company.
- Investors who purchased Sage securities prior to April 12, 2021, and continue to hold are encouraged to obtain additional information and assist the investigation.
- Potential harm to individual investors includes significant financial losses and potential damage to their portfolios.
- The investigation could have far-reaching implications for the biopharmaceutical industry and investors.
